• Post-Doctoral Research Fellow, B Cell Immunology and Vaccines

    Job ID
    11078
    Type
    Regular Full-Time
    Company
    Fred Hutchinson Cancer Research Center
    Location
    US-WA-Seattle
    Category
    Post-Doctoral Research Fellows and Associates
  • Overview

    Cures Start Here. At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutch’s pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nation’s first cancer prevention research program, as well as the clinical coordinating center of the Women’s Health Initiative and the international headquarters of the HIV Vaccine Trials Network. Careers Start Here.

     

    The Stamatatos Lab (https://research.fhcrc.org/stamatatos/en.html), within the Vaccine and Infectious Disease Division of the Fred Hutchinson Cancer Research Center, focuses on developing immunization approaches to expand and guide the maturation of particular B cell lineages along specific evolutionary pathways that result in the production of protective antibodies against infectious agents. We employ a wide range of experimental approaches, including deep sequencing and bioinformatic analysis of B cell receptor repertoires, structure-based immunogen-design, immunological, molecular and cellular biology techniques, crystallography, and knock-in and transgenic animals.  Our work includes the pre-clinical and clinical evaluation of candidate vaccines.

    Responsibilities

    Our Lab is seeking outstanding Post doctoral Fellows to work on developing and testing new immunogens and immunization protocols to guide the maturation of particular B cell clones along specific evolutionary pathways in animals and humans.

     

    Major Duties:

    • Primary B cell analyses upon immunization of knock-in and transgenic mice
    • Protein immunogen design, expression and characterization
    • May involve use of Yeast-display approaches
    • Initiate and carry out scientific projects, under the supervision of Dr. Stamatatos
    • Develop and demonstrate a thorough understanding of the scientific literature relating to the research topics.
    • Conduct and publish research in appropriate journals.

    Qualifications

    PhD in T or B cell immunology. Expertise in diverse immunochemical and molecular approaches is required. Additional expertise in Yeast-display approaches is a plus. The candidates must show initiative, willingness to take up new skills and responsibilities, and be a team player. Excellent attention to details and the ability to work independently are essential to success in this position, as are good communication and organizational skills. The candidates must be self-motivated, able to multitask and to work within a very collaborative environment. Salary will be commensurate with appropriate experience.

    Our Commitment to Diversity

    We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We are proud to be an Equal Opportunity and VEVRAA Employer. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. If due to a disability you need assistance/and or a reasonable accommodation during the application or recruiting process, please send a request to our Employee Services Center at escmail@fredhutch.org or by calling 206-667-4700.

    Options

    Sorry the Share function is not working properly at this moment. Please refresh the page and try again later.
    Share on your newsfeed